Herrlinger C, Klotz U
Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D-70376 Stuttgart, Germany.
Best Pract Res Clin Gastroenterol. 2001 Dec;15(6):897-918. doi: 10.1053/bega.2001.0249.
In the elderly concomitant use of several drugs (polypharmacy) is very common. Thus, the risk for drug interactions might be increased in this population. Since most drugs are hepatically eliminated by various metabolic pathways, liver function has to be considered as an additional factor modifying drug response. This chapter focuses on the hepatic mechanisms of interactions, especially on various inhibitors and inducers of the most important cytochrome P450 isoenzymes involved in drug metabolism. In addition, age-dependent changes in liver function are addressed. Based on pharmacokinetic results with different probe drugs, some inconsistencies in this area are discussed. The most important metabolic drug-drug interactions are independent of the age of the patients. However, since elderly patients consume a greater proportional share of drugs, they represent a population at risk for interactions. Awareness of this clinical problem may help to diminish those risks.
在老年人中,同时使用多种药物(多重用药)非常普遍。因此,这一人群中药物相互作用的风险可能会增加。由于大多数药物通过各种代谢途径经肝脏消除,肝功能必须被视为影响药物反应的另一个因素。本章重点关注相互作用的肝脏机制,特别是参与药物代谢的最重要细胞色素P450同工酶的各种抑制剂和诱导剂。此外,还讨论了肝功能随年龄的变化。基于不同探针药物的药代动力学结果,探讨了该领域的一些不一致之处。最重要的代谢性药物相互作用与患者年龄无关。然而,由于老年患者使用的药物比例更大,他们是发生相互作用的风险人群。认识到这一临床问题可能有助于降低这些风险。